Please wait a minute...
Reviews in Cardiovascular Medicine  2014, Vol. 15 Issue (S1): 30-37     DOI: 10.3908.ricm15S1S003
Review Previous articles | Next articles
Impact of Antiretroviral Medications on Fasting Lipid Parameters
Giovanni Guaraldi1, Antonella Santoro1, Chiara Stentarelli1, Kety Luzi2
1 Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Italy
2 Infectious Disease Clinic, Azienda USL 4 Prato, Italy
Download:  PDF(208KB)  ( 119 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
It is widely accepted that metabolic disease in human immunodeficiency virus (HIV) develops at the intersection of traditional risk factors and HIV-specific contributors, but in observational studies it is difficult to dissect the contribution of the two. This review describes the metabolic impact of antiretroviral medications recommended in the first-line treatment in HIV-infected naive patients. At a clinical level, coronary heart disease screening and management will continue to be of paramount importance in the long-term management of HIV-positive patients on antiretroviral therapy.
Key words:  Coronary heart disease      Human immunodeficiency virus      Antiretroviral therapy      Dyslipidemia     
Published:  20 January 2014     

Cite this article: 

Giovanni Guaraldi, Antonella Santoro, Chiara Stentarelli, Kety Luzi. Impact of Antiretroviral Medications on Fasting Lipid Parameters. Reviews in Cardiovascular Medicine, 2014, 15(S1): 30-37.

URL: 

https://rcm.imrpress.com/EN/10.3908.ricm15S1S003     OR     https://rcm.imrpress.com/EN/Y2014/V15/IS1/30

[1] Yun Tian, Pingji Deng, Bing Li, Jieqiong Wang, Ju Li, Yulan Huang, Yan Zheng. Treatment models of cardiac rehabilitation in patients with coronary heart disease and related factors affecting patient compliance[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 27-33.
[2] Jun Zhang, Natalia de Albuquerque Rocha, and Peter A. McCullough. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen[J]. Reviews in Cardiovascular Medicine, 2018, 19(1): 13-19.
[3] Vasiliki Katsi, Manolis S. Kallistratos, Antonios N. Pavlidis, Nikos Karpettas, Ioannis Skoumas, Nikonas Pavleros, Athanasios J. Manolis, Christos Pitsavos, Dimitris Tousoulis, Christodoulos Stefanadis, Ioannis Kallikazaros. The Mystery of High-density Lipoprotein: Quantity or Quality? Update on Therapeutic Strategies[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 9-19.
[4] Virginia A. Triant. Epidemiology of Coronary Heart Disease in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 1-8.
[5] Paolo Gresele, Emanuela Falcinelli, Stefania Momi, Daniela Francisci, Franco Baldelli. Highly Active Antiretroviral Therapy–related Mechanisms of Endothelial and Platelet Function Alterations[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 9-20.
[6] Patrick W.G. Mallon. Impact of Nucleoside Reverse Transcriptase Inhibitors on Coronary Heart Disease[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 21-29.
[7] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38-46.
[8] Peter A. McCullough, Amina B. Ahmed, Marc T. Zughaib, Eric D. Glanz, Michael J. Di Loreto. Treatment of Hypertriglyceridemia With Fibric Acid Derivatives: Impact on Lipid Subfractions and Translation Into a Reduction in Cardiovascular Events[J]. Reviews in Cardiovascular Medicine, 2011, 12(4): 173-185.
[9] Paula Bernstein, Gerald Pohost. Progesterone, Progestins, and the Heart[J]. Reviews in Cardiovascular Medicine, 2010, 11(4): 228-236.
[10] Karol E. Watson. Pitavastatin: The Newest HMG-CoA Reductase Inhibitor[J]. Reviews in Cardiovascular Medicine, 2010, 11(1): 26-32.
[11] Norman E. Lepor. Best of the AHA Scientific Sessions 2009[J]. Reviews in Cardiovascular Medicine, 2009, 10(4): 224-231.
[12] William B. Borden, Michael H. Davidson. Updating the Assessment of Cardiac Risk: Beyond Framingham[J]. Reviews in Cardiovascular Medicine, 2009, 10(2): 63-71.
[13] Karol E. Watson. The JUPITER Trial: How Will It Change Clinical Practice?[J]. Reviews in Cardiovascular Medicine, 2009, 10(2): 91-96.
[14] Karol E. Watson, Alice K. Jacobs, Norman E. Lepor. Best of the AHA Scientific Sessions 2008[J]. Reviews in Cardiovascular Medicine, 2009, 10(1): 43-50.
[15] Gustavo A. Cardenas, Carl J. Lavie, Vanessa Cardenas, Richard V. Milani, Peter A. McCullough. The Importance of Recognizing and Treating Low Levels of High-Density Lipoprotein Cholesterol: A New Era in Atherosclerosis Management[J]. Reviews in Cardiovascular Medicine, 2008, 9(4): 239-258.
No Suggested Reading articles found!